Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.

Autor: Panaite L; Department of Medicine, University of Washington, Seattle, WA, USA., Wu QV; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Voutsinas J; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Mullane E; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Chow VA; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Lynch RC; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Ujjani CS; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Smith SD; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Gopal AK; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Poh C; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Iovino L; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Turtle CJ; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Maloney DG; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Till BG; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Gauthier J; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA., Shadman M; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutch, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2918-2922. Date of Electronic Publication: 2022 Jul 09.
DOI: 10.1080/10428194.2022.2095632
Abstrakt: Cytopenias are important but less studied adverse events following chimeric antigen receptor-engineered T cell (CAR-T) therapy. In our analysis of patients with large cell lymphoma who received axicabtagene ciloleucel (axi-cel), we sought to determine the rate and risk factors of clinically significant short term cytopenias defined as grade ≥3 neutropenia, anemia, or thrombocytopenia, or treatment with growth factors or blood product transfusions between days 20-30 after axi-cel. Fifty-three pts received axi-cel during the study period and severe cytopenias were observed in 32 (60%) pts. Significant cytopenias were more common in non-responders (stable or progressive disease) vs. responders (partial or complete response) (100% vs. 70%; p = .01). In the multivariable model, platelet transfusion within a month before leukapheresis, number of red blood cell and platelet transfusions between leukapheresis to lymphodepletion, pre-lymphodepletion absolute neurophil count, pre-lymphodepletion lactate dehydrogenase, and number of dexamethasone treatments after CAR-T were significantly associated with severe cytopenias after axi-cel.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje